Tezepelumab is a HuMAb that inhibits the action of thymic stromal lymphopoietin (TSLP)—an epithelial cell-derived cytokine that is implicated in the pathogenesis of CRS. The gene discussed is TSLP; the disease is congenital rubella syndrome.